Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genomics

The path to retinoblastoma

Nature volume 481, pages 269–270 (2012)Cite this article

Subjects

Genomic analyses of tumours of the childhood cancer retinoblastoma reveal a low mutation rate, challenging the view that genomic instability is crucial for its progression. The work also identifies a new therapeutic target. See Article p.329

Retinoblastoma is a rare tumour that affects retinal cells in the eyes of children. Analyses of familial and sporadic cases of this cancer, backed by studies in genetically engineered mice, have shown that loss of function of the tumour-suppressor protein RB1 (also known as RB) is required for the development of most, if not all, tumours of this type. However, it is not clear how RB1-deficient retinal cells progress to malignant tumour cells1. In addition, emerging evidence that loss of RB1 function can induce genomic instability2 has raised the tantalizing possibility that RB1-deficient retinal cells might be predisposed to accumulating many additional mutations, further complicating the identification of mutations that contribute to the development and maintenance of retinoblastoma. On page 329 of this issue, however, Zhang et al.3 demonstrate that retinoblastoma genomes have very few recurrent mutations in genes other than RB1. Instead, the expression of cancer-related genes is affected by epigenetic modifications on chromosomes, which do not affect DNA sequence but are inherited after cell division.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chinnam, M. & Goodrich, D. W. Curr. Top. Dev. Biol. 94, 129–169 (2011).

    Article  CAS  Google Scholar 

  2. Manning, A. L. & Dyson, N. J. Trends Cell Biol. 21, 433–441 (2011).

    Article  CAS  Google Scholar 

  3. Zhang, J. et al. Nature 481, 329–334 (2012).

    Article  ADS  CAS  Google Scholar 

  4. Stratton, M. R. Science 331, 1553–1558 (2011).

    Article  ADS  CAS  Google Scholar 

  5. Parsons, D. W. et al. Science 331, 435–439 (2011).

    Article  ADS  CAS  Google Scholar 

  6. Hansen, K. D. et al. Nature Genet. 43, 768–775 (2011).

    Article  CAS  Google Scholar 

  7. Ng, D. et al. Nature Genet. 36, 411–416 (2004).

    Article  CAS  Google Scholar 

  8. Fan, Z. et al. Nature Cell Biol. 11, 1002–1009 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Julien Sage is in the Departments of Pediatrics and of Genetics, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA.,

    Julien Sage

  2. Michael L. Cleary is in the Departments of Pathology and of Pediatrics, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA.,

    Michael L. Cleary

Authors
  1. Julien Sage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael L. Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Julien Sage or Michael L. Cleary.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sage, J., Cleary, M. The path to retinoblastoma. Nature 481, 269–270 (2012). https://doi.org/10.1038/481269a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/481269a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer